Low-cost polypill could dramatically cut heart attacks, strokesA single tablet that contains four generically-available drugs – or ‘polypill’ – could offer an effective, low-cost way Share XLow-cost polypill could dramatically cut heart attacks, strokeshttps://pharmaphorum.com/news/low-cost-polypill-could-dramatically-cut-heart-attacks-strokes/
AZ’s Forxiga gets heart claim data on its EU labelAstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 Share XAZ’s Forxiga gets heart claim data on its EU labelhttps://pharmaphorum.com/news/azs-forxiga-gets-heart-claim-data-on-its-eu-label/
FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failureEli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease Share XFDA fast-tracks Lilly/Boehringer’s Jardiance for heart failurehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-for-heart-failure/
Pfizer and Merck’s diabetes contender looks to challenge JardianceMerck and Pfizer have Boehringer and Lilly in their sights with ertugliflozin Share XPfizer and Merck’s diabetes contender looks to challenge Jardiancehttps://pharmaphorum.com/news/pfizer-merck-file-diabetes-contender-us-eu/